Last month, the European Commission and a coalition of European Industry associations published a draft Strategic Research and Innovation Agenda (SRIA). The SRIA will guide the work that is carried out in the proposed Innovative Health Initiative framework, the Horizon Europe successor to the Horizon 2020-cofunded Innovative Medicines Initiative 2 Joint Undertaking (IMI2 JU).
Building on lessons learned from IMI2 JU, which was the world's largest public-private partnership (PPP) focused on accelerating drug development, the SRIA for the proposed Innovative Health Initiative (IHI) brings new partners and stakeholders to the table. Co-developed by five Industry associations (COCIR, EFPIA, EuropaBio, MedTech Europe and Vaccines Europe) and the European Commission, the SRIA identifies the scope, objectives and activities of the IHI. The proposed IHI will cover the entire continuum of care, from prevention and diagnostics to treatment and disease management. General objectives include; 1) the creation of an EU-wide research and innovation system for healthcare; 2) fostering the development of safe, effective and people-centric innovations that respond to unmet public health needs; and 3) driving cross-sectoral health innovation, towards a globally competitive European health industry.
